High dexamethasone concentration prevents stimulatory effects of TNF-α and LPS on IL-6 secretion from the precursors of human muscle regeneration

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 291, Issue 6, 2006, Pages

  Prelovsek, Oja ^a   Mars, Tomaz ^a   Jevsek, Marko ^a   Podbregar, Matej ^a,b   Grubic, Zoran ^a,c  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^c UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Critical illness myopathy; Cytokines; Glucocorticoids; Myoblasts; Myotubes; Sepsis induced myopathy

Indexed keywords

DEXAMETHASONE; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; CONTROLLED STUDY; CRITICALLY ILL PATIENT; CYTOKINE RELEASE; DOSE RESPONSE; DRUG MECHANISM; HUMAN; HUMAN CELL; HUMAN TISSUE; MUSCLE DEVELOPMENT; MUSCLE FIBER CULTURE; MUSCLE REGENERATION; MYOBLAST; MYOTUBE; NECROSIS; PARACRINE SIGNALING; PRIORITY JOURNAL;

CELL DIFFERENTIATION; CELLS, CULTURED; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; GRANULOCYTE PRECURSOR CELLS; HUMANS; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MUSCLE, SKELETAL; MYOBLASTS, SKELETAL; REGENERATION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33845425133     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00020.2006     Document Type: Article

References (38)

1. Askanas V, Kwan H, Alvarez RB, Engel WK, Kobayashi T, Martinuzzi A, and Hawkins EF. De novo neuromuscular junction formation on human muscle fibers cultured in monolayer and innervated by foetal rat spinal cord: ultrastructural and ultrastructural-cytochemical studies. J Neurocyto 16: 523-537, 1987.
2. Austin L, Bower J, Kurek J, and Vakakis N. Effects of leukaemia inhibitory factor and other cytokines on murine and human myoblast proliferation. J Neurol Sci 112: 185-191, 1992.
3. Austin L and Burgess AW. Stimulation of myoblast proliferation in culture by leukaemia inhibitory factor and other cytokines. J Neurol Sci 101: 193-197, 1991.
4. Baeza-Raja B and Munoz-Canoves P. p38 MAPK-induced nuclear factor-kappaB activity is required for skeletal muscle differentiation: role of interleukin-6. Mol Biol Cell 15: 2013-2026, 2004.
5. Balk RA. Steroids for septic shock: back from the dead? Chest 123: 490S-499S, 2003.
6. Bartoccioni E, Michaelis D, and Hohlfeld R. Constitutive and cytokine-induced production of interleukin-6 by human myoblasts. Immunol Lett 42: 135-138, 1994.
7. Belge KU, Dayyani F, Horelt A, Siedlar M, Frankenberger M, Frankenberger B, Espevik T, and Ziegler-Heitbrock L. The proinflammatory CD14+CD16+DR++ monocytes are a major source of TNF. J Immunol 168: 3536-3542, 2002.
8. Bischoff R. The satellite cell and muscle regeneration. In: Myology, edited by Engel AG and Franzini-Armstrong C: New York: McGraw Hill, 1994, p. 97-118.
9. Bolton CF. Neuromuscular manifestations of critical illness. Muscle Nerve 32: 140-63, 2005.
10. Brandtzaeg P, Osnes L, Ovstebo R, Joo GB, Westvik AB, and Kierulf P. Net inflammatory capacity of human septic shock plasma evaluated by a monocyte-based target cell assay: identification of interleukin-10 as a major functional deactivator of human monocytes. J Exp Med 184: 51-60, 1996.
11. Cantini M, Massimino ML, Rapizzi E, Rossini K, Catani C, Dalla Libera L, and Carraro U. Human satellite cell proliferation in vitro is regulated by autocrine secretion of IL-6 stimulated by a soluble factor(s) released by activated monocytes. Biochem Biophys Res Commun 216: 49-53, 1995.
12. Carballo-Jane E, Pandit S, Santoro JC, Freund C, Luell S, Harris G, Forrest MJ, and Sitlani A. Skeletal muscle: a dual system to measure glucocorticoid-dependent transactivation and transrepression of gene regulation. J Steroid Biochem Mol Biol 88: 191-201, 2004.
13. De S, Zelazny ET, Souhrada JF, and Souhrada M. IL-1 beta and IL-6 induce hyperplasia and hypertrophy of cultured guinea pig airway smooth muscle cells. J Appl Physiol 78: 1555-1563, 1995.
14. de Letter MA, Schmitz PI, Visser LH, Verheul FA, Schellens RL, Op de Coul DA, and van der Meche FG. Risk factors for the development of polyneuropathy and myopathy in critically ill patients. Crit Care Med 29: 2281-2286, 2001.
15. Derouich-Guergour D, Aldebert D, Vigan I, Jouvin-Marche E, Marche PN, Aubert D, Ambroise-Thomas P, and Pelloux H. Toxoplasma gondii infection can regulate the expression of tumour necrosis factor-alpha receptors on human cells in vitro. Parasite Immunol 24: 271-279, 2002.
16. Dougherty CJ, Kubasiak LA, Prentice H, Andreka P, Bishopric NH, and Webster KA. Activation of c-Jun N-terminal kinase promotes survival of cardiac myocytes after oxidative stress. Biochem J 362: 561-571, 2002.
17. Febbraio MA and Pedersen BK. Contraction-induced myokine production and release: is skeletal muscle an endocrine organ? Exerc Sport Sci Rev 33: 114-119, 2005.
18. Franchimont D. Overview of the actions of glucocorticoids on the immune response: a good model to characterize new pathways of immunosuppression for new treatment strategies. Ann NY Acad Sci 1024: 124-137, 2004.
19. Frost RA, Nystrom GJ, and Lang CH. Lipopolysaccharide regulates proinflammatory cytokine expression in mouse myoblasts and skeletal muscle. Am J Physiol Regul Integr Comp Physiol 283: R698-R709, 2002.
20. Frost RA, Nystrom GJ, and Lang CH. Multiple toll-like receptor ligands induce an IL-6 transcriptional response in skeletal myoctyes. Am J Physiol Regul Integr Comp Physiol 290: R773-R784, 2006.
21. Grubic Z, Komel R, Walker WF, and Miranda AF. Myoblast fusion and innervation with rat motor nerve alter distribution of acetylcholinesterase and its mRNA in cultures of human muscle. Neuron 14: 317-27, 1995.
22. Hauschka SD. Development, anatomy, and cell biology. In: Myology (2nd ed.), edited by Engel AG and Franzini-Armstrong C. New York: McGraw Hill, 1994, p. 3-73.
23. Kaminski HJ and Ruff RL. Endocrine myopathies (hyper- and hypofunction of adrenal, thyroid, pituitary, and parathyroid glands and iatrogenic corticosteroid myopathy). In: Myology, edited by Engel AG and Franzini-Armstrong C. New York: McGraw-Hill, 1994, p. 1726-1753.
24. Latronico N, Shehu I, and Seghelini E. Neuromuscular sequelae of critical illness. Curr Opin Crit Care 11: 381-390, 2005.
25. Lee SC, Liu W, Dickson DW, Brosnan CF, and Berman JW. Cytokine production by human fetal microglia and astrocytes. Differential induction by lipopolysaccharide and IL-1 beta. J Immunol 150: 2659-2667, 1993.
26. Mars T, Yu KJ, Tang XM, Miranda AF, Grubic Z, Cambi F, and King MP. Differentiation of glial cells and motor neurons during the formation of neuromuscular junctions in cocultures of rat spinal cord explant and human muscle. J Comp Neurol 438: 239-251, 2001.
27. McPhee SJ. Disorders of the adrenal cortex. In: Pathophysiology of Disease, edited by McPhee SJ, Lingappa VR, Ganong WF, and Lange JD. New York: McGraw-Hill, 2000, p. 500-528.
28. Meduri GU, Chinn AJ, and Leeper KV. Corticosteroid rescue treatment of progressive fibroproliferation in late ARDS: patterns of response and predictors of outcome. Chest 105: 1516-1527, 1994.
29. Natarajan K, Manna SK, Chaturvedi MM, and Aggarwal BB. Protein tyrosine kinase inhibitors block tumor necrosis factor-induced activation of nuclear factor-kappaB, degradation of IkappaBalpha, nuclear translocation of p65, and subsequent gene expression. Arch Biochem Biophys 352: 59-70, 1998.
30. Pan ZK. Toll-like receptors and TLR-mediated signaling: more questions than answers. Am J Physiol Lung Cell Mol Physiol 286: L918-L920, 2004.
31. Papanicolaou DA, Petrides JS, Tsigos C, Bina S, Kalogeras KT, Wilder R, Gold PW, Deuster PA, and Chrousos GP. Exercise stimulates interleukin-6 secretion: inhibition by glucocorticoids and correlation with catecholamines. Am J Physiol Endocrinol Metab 271: E601-E605, 1996.
32. Schimmer BP and Parker KL. Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones. In: Goodman & Gilman's The Pharmacological Basis of Therapeutics, edited by Brunton LL, Lazo JS, and Parker LL. New York: McGraw-Hill, 2006, p. 1587-1612.
33. Schroeder S, Wichers M, Klingmuller D, Hofer M, Lehmann LE, von Spiegel T, Hering R, Putensen C, Hoeft A, and Stuber F. The hypothalamic-pituitary- adrenal axis of patients with severe sepsis: altered response to corticotropin-releasing hormone. Crit Care Med 29: 310-316, 2001.
34. Schwandner R, Dziarski R, Wesche H, Rothe M, and Kirschning CJ. Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by toll-like receptor 2. J Biol Chem 274: 17406-17409, 1999.
35. Singleton JR, Brandi Baker L, and Thorburn A. Dexamethasone inhibits insulin-like growth factor signaling and potentiates myoblast apoptosis. Endocrinology 141: 2945-2950, 2000.
36. Vandenabeele P, Declercq W, Beyaert R, and Fiers W. Two tumour necrosis factor receptors: structure and function. Trends Cell Biol 5: 392-399, 1995.
37. Wirtz PH, von Kanel R, Kunz-Ebrecht S, Ehlert U, and Fischer JE. Reduced glucocorticoid sensitivity of monocyte interleukin-6 release in male employees with high plasma levels of tumor necrosis factor-alpha. Life Sci 75: 1-10, 2004.
38. Yang RB, Mark MR, Gray A, Huang A, Xie MH, Zhang M, Goddard A, Wood WI, Gurney AL, and Godowski PJ. Toll-like receptor-2 mediates lipopolysaccharide- induced cellular signalling. Nature 395: 284-288, 1998.